186 related articles for article (PubMed ID: 32408777)
1. The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer.
Wall JA; Klempner SJ; Arend RC
Expert Opin Investig Drugs; 2020 Jul; 29(7):639-644. PubMed ID: 32408777
[TBL] [Abstract][Full Text] [Related]
2. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Arend R; Dholakia J; Castro C; Matulonis U; Hamilton E; Jackson CG; LyBarger K; Goodman HM; Duska LR; Mahdi H; ElNaggar AC; Kagey MH; Liu A; Piper D; Barroilhet LM; Bradley W; Sachdev J; Sirard CA; O'Malley DM; Birrer M
Gynecol Oncol; 2023 May; 172():82-91. PubMed ID: 37001446
[TBL] [Abstract][Full Text] [Related]
3. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Goyal L; Sirard C; Schrag M; Kagey MH; Eads JR; Stein S; El-Khoueiry AB; Manji GA; Abrams TA; Khorana AA; Miksad R; Mahalingam D; Zhu AX; Duda DG
Clin Cancer Res; 2020 Dec; 26(23):6158-6167. PubMed ID: 32878766
[TBL] [Abstract][Full Text] [Related]
4. Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.
Klempner SJ; Bendell JC; Villaflor VM; Tenner LL; Stein SM; Rottman JB; Naik GS; Sirard CA; Kagey MH; Chaney MF; Strickler JH
Mol Cancer Ther; 2021 Nov; 20(11):2240-2249. PubMed ID: 34482288
[TBL] [Abstract][Full Text] [Related]
5. mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment.
Haas MS; Kagey MH; Heath H; Schuerpf F; Rottman JB; Newman W
Mol Cancer Res; 2021 Apr; 19(4):717-725. PubMed ID: 33443105
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Wise DR; Pachynski RK; Denmeade SR; Aggarwal RR; Deng J; Febles VA; Balar AV; Economides MP; Loomis C; Selvaraj S; Haas M; Kagey MH; Newman W; Baum J; Troxel AB; Griglun S; Leis D; Yang N; Aranchiy V; Machado S; Waalkes E; Gargano G; Soamchand N; Puranik A; Chattopadhyay P; Fedal E; Deng FM; Ren Q; Chiriboga L; Melamed J; Sirard CA; Wong KK
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38341461
[TBL] [Abstract][Full Text] [Related]
7. Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
Betella I; Turbitt WJ; Szul T; Wu B; Martinez A; Katre A; Wall JA; Norian L; Birrer MJ; Arend R
Gynecol Oncol; 2020 Jun; 157(3):765-774. PubMed ID: 32192732
[TBL] [Abstract][Full Text] [Related]
8. Dickkopf-1: A Promising Target for Cancer Immunotherapy.
Chu HY; Chen Z; Wang L; Zhang ZK; Tan X; Liu S; Zhang BT; Lu A; Yu Y; Zhang G
Front Immunol; 2021; 12():658097. PubMed ID: 34093545
[TBL] [Abstract][Full Text] [Related]
9. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.
Sato N; Yamabuki T; Takano A; Koinuma J; Aragaki M; Masuda K; Ishikawa N; Kohno N; Ito H; Miyamoto M; Nakayama H; Miyagi Y; Tsuchiya E; Kondo S; Nakamura Y; Daigo Y
Cancer Res; 2010 Jul; 70(13):5326-36. PubMed ID: 20551066
[TBL] [Abstract][Full Text] [Related]
10. DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01.
Jarman EJ; Horcas-Lopez M; Waddell SH; MacMaster S; Gournopanos K; Soong DYH; Musialik KI; Tsokkou P; Ng ME; Cambridge WA; Wilson DH; Kagey MH; Newman W; Pollard JW; Boulter L
Liver Int; 2023 Jan; 43(1):208-220. PubMed ID: 35924447
[TBL] [Abstract][Full Text] [Related]
11. Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers.
Qian J; Wang Q; Xiao L; Xiong W; Xian M; Su P; Yang M; Zhang C; Li Y; Zhong L; Ganguly S; Zu Y; Yi Q
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38267222
[TBL] [Abstract][Full Text] [Related]
12. Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology.
Kagey MH; He X
Br J Pharmacol; 2017 Dec; 174(24):4637-4650. PubMed ID: 28574171
[TBL] [Abstract][Full Text] [Related]
13. Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance.
Dholakia J; Scalise CB; Katre AA; Goldsberry WN; Meza-Perez S; Randall TD; Norian LA; Novak L; Arend RC
Gynecol Oncol; 2022 Jan; 164(1):170-180. PubMed ID: 34844776
[TBL] [Abstract][Full Text] [Related]
14. Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors.
Caldwell C; Rottman JB; Paces W; Bueche E; Reitsma S; Gibb J; Adisetiyo V; Haas MS; Heath H; Newman W; Baum J; Gianani R; Kagey MH
Sci Rep; 2021 May; 11(1):9920. PubMed ID: 33972574
[TBL] [Abstract][Full Text] [Related]
15. Dickkopf-1, the Wnt antagonist, is induced by acidic pH and mediates epithelial cellular senescence in human reflux esophagitis.
Lyros O; Rafiee P; Nie L; Medda R; Jovanovic N; Schmidt J; Mackinnon A; Venu N; Shaker R
Am J Physiol Gastrointest Liver Physiol; 2014 Apr; 306(7):G557-74. PubMed ID: 24481601
[TBL] [Abstract][Full Text] [Related]
16. STAT1-induced upregulation of LINC00467 promotes the proliferation migration of lung adenocarcinoma cells by epigenetically silencing DKK1 to activate Wnt/β-catenin signaling pathway.
Yang J; Liu Y; Mai X; Lu S; Jin L; Tai X
Biochem Biophys Res Commun; 2019 Jun; 514(1):118-126. PubMed ID: 31027730
[TBL] [Abstract][Full Text] [Related]
17. Chimeric 5/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44⁺ gastric cancer cells via attenuating Wnt signaling.
Wang B; Liu J; Ma LN; Xiao HL; Wang YZ; Li Y; Wang Z; Fan L; Lan C; Yang M; Hu L; Wei Y; Bian XW; Chen D; Wang J
J Gastroenterol; 2013 Jul; 48(7):798-808. PubMed ID: 23188090
[TBL] [Abstract][Full Text] [Related]
18. Wnt/β-Catenin Signaling Activation beyond Robust Nuclear β-Catenin Accumulation in Nondysplastic Barrett's Esophagus: Regulation via Dickkopf-1.
Lyros O; Rafiee P; Nie L; Medda R; Jovanovic N; Otterson MF; Behmaram B; Gockel I; Mackinnon A; Shaker R
Neoplasia; 2015 Jul; 17(7):598-611. PubMed ID: 26297437
[TBL] [Abstract][Full Text] [Related]
19. Dkk1 exacerbates doxorubicin-induced cardiotoxicity by inhibiting the Wnt/β-catenin signaling pathway.
Liang L; Tu Y; Lu J; Wang P; Guo Z; Wang Q; Guo K; Lan R; Li H; Liu P
J Cell Sci; 2019 May; 132(10):. PubMed ID: 31028181
[TBL] [Abstract][Full Text] [Related]
20. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo.
Glantschnig H; Hampton RA; Lu P; Zhao JZ; Vitelli S; Huang L; Haytko P; Cusick T; Ireland C; Jarantow SW; Ernst R; Wei N; Nantermet P; Scott KR; Fisher JE; Talamo F; Orsatti L; Reszka AA; Sandhu P; Kimmel D; Flores O; Strohl W; An Z; Wang F
J Biol Chem; 2010 Dec; 285(51):40135-47. PubMed ID: 20929859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
